Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Matthew C Winter"'
Autor:
Victoria L. Parker, Matthew C. Winter, John A. Tidy, Barry W. Hancock, Julia E. Palmer, Naveed Sarwar, Baljeet Kaur, Katie McDonald, Xianne Aguiar, Kamaljit Singh, Nick Unsworth, Imran Jabbar, Allan A. Pacey, Robert F. Harrison, Michael J. Seckl
Publikováno v:
International journal of cancerREFERENCES. 152(5)
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is
Autor:
Matthew C. Winter
Publikováno v:
Best Practice & Research Clinical Obstetrics & Gynaecology. 74:67-80
Low-risk gestational trophoblastic neoplasia (GTN), defined as FIGO/WHO score 0-6, is highly curable with an overall survival rate, which is approximately 100%. For most low-risk GTN patients, first-line single-agent chemotherapy with either methotre
Autor:
Victoria L. Parker, Bryony F. Cushen, Annie Hills, Kaveetha Kandiah, Julia E. Palmer, Kamaljit Singh, Barry W. Hancock, John A. Tidy, Matthew C. Winter
Publikováno v:
Gynecologic oncology. 169
Single-agent methotrexate (MTX) is commonly used as first-line treatment for low-risk gestational trophoblastic neoplasia (LR-GTN), although no international consensus exists on the optimal treatment regimen to maximise complete hCG response (CR) and
Autor:
Margot Gosney, Alistair Ring, R. Parmeschwar, Kate Lifford, Deirdre Revill, Lynda Wyld, Jacqui Gath, Jenna Morgan, Annaliza Todd, Geoffrey Holmes, Charlene Martin, Sue Ward, A.M. Thomson, Tim Chater, Anne Shrestha, Malcolm W.R. Reed, Adrian Edwards, Mike Bradburn, Matthew Hatton, Alan Brennan, Kirsty Pemberton, Jay Naik, Christopher Holcombe, Kwok-Leung Cheung, Thompson G. Robinson, J.T. Wright, T. Green, Stephen J Walters, Matthew C Winter, Maria Burton, Karen Collins, Esther Herbert, Riccardo A. Audisio, Richard Simcock, Kieran Horgan
Publikováno v:
British Journal of Surgery. 108:315-325
Background Primary endocrine therapy may be an alternative treatment for less fit women with oestrogen receptor (ER)-positive breast cancer. This study compared quality-of-life (QoL) outcomes in older women treated with surgery or primary endocrine t
Autor:
Lynda Wyld, Richard Simcock, Jacqui Gath, Alan Brennan, Deirdre Revell, Maria Burton, Riccardo A. Audisio, Jay Naik, Malcolm W.R. Reed, Kwok L. Cheung, Geoffrey Holmes, Charlene Martin, Annaliza Todd, Matthew Hatton, Tim Chater, Kirsty Pemberton, Stephen J Walters, Chris Holcombe, Matthew C Winter, Margot Gosney, Thompson G. Robinson, Kate Lifford, Adrian Edwards, A. Ring, Anne Shrestha, Kieran Horgan, Sue Ward, Juliet Wright, Alastair M. Thompson, Karen Collins, Rishi Parmeshwar, Nicolò Matteo Luca Battisti, Esther Herbert, Jenna Morgan, Age Gap Tmg, Tracey Green, Mike Bradburn
Publikováno v:
European Journal of Cancer
Introduction Older patients with early breast cancer (EBC) derive modest survival benefit from chemotherapy but have increased toxicity risk. Data on the impact of chemotherapy for EBC on quality of life in older patients are limited, but this is a k
Autor:
Allan A. Pacey, Elspeth H. Whitby, William A E Parker, Barry W. Hancock, Matthew C Winter, John Tidy, Julia E. Palmer, Victoria L. Parker, Robert F. Harrison
Publikováno v:
British Journal of Cancer
Background The International Federation of Gynaecology and Obstetrics (FIGO) score identifies gestational trophoblastic neoplasia (GTN) patients as low- or high-risk of single-agent chemotherapy resistance (SACR). Computed tomography (CT) has greater
Autor:
Matthew C Winter, Daniel Rea, Jacinta Abraham, Olga Oikonomidou, Iain R. Macpherson, David Cameron, Jeremy P Braybrooke, Sarah Kernaghan, Andrew M Wardley, Heidrun Gevensleben, Laura Moretti, Mark Tuthill, Katrina Randle, Peter Stephens, A Ring, Mike Hubank, Judith M Bliss, Rebecca Roylance, Abeer M Shaaban, Hannah Bye, Lucy Kilburn, Sue Martin, B Kingston, Katie Wilkinson, Nicholas C. Turner, Claire Snowdon, Ros Cutts, Richard D. Baird
Publikováno v:
C Turner, N, Kingston, B, S Kilburn, L, Kernaghan, S, M Wardley, A, R Macpherson, I, D Baird, R, Roylance, R, Stephens, P, Oikonomidou, O, P Braybrooke, J, Tuthill, M, Abraham, J, C Winter, M, Bye, H, Hubank, M, Gevensleben, H, Cutts, R, Snowdon, C, Rea, D, Cameron, D A, Shaaban, A, Randle, K, Martin, S, Wilkinson, K, Moretti, L, Bliss, J M & Ring, A 2020, ' Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial ', The Lancet Oncology, vol. 21, no. 10, pp. 1296-1308 . https://doi.org/10.1016/S1470-2045(20)30444-7
BACKGROUND: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing in advanced breast cancer and
Autor:
Lone Sunde, Kirsty Balanchandran, Minke Frijstein, Georgia Mangili, Sileny Han, Miguel Henriques Abreu, Nataliya Tsip, Anneke M. Westermann, Vilmos Fulop, Franziska Siegenthaler, Michael J. Seckl, Manuela Undurraga, John Coulter, Anne Hills, Angela Salerno, Kamaljit Singh, Lotte Boog, Jacob Korach, Nelleke Ottevanger, Jérôme Massardier, Ulrika Joneborg, Eva Maria Roes, Frédéric Goffin, Luisa Skupin, Fernando Manuel Ribeiro Gomes, Alice Bergamini, Jane Ireson, Benoit You, Catriona Kenneally, Miroslav Korbel, Saša Kadija, Vildana Finci, Isa Niemann, Sarah Delcominette, Antonio Casado, Gloria Marquina, Pierre Adrien Bolze, Grzegorz Szewczyk, François Golfier, Nienke E. van Trommel, Naveed Sarwar, Raffaella Cioffi, Cantù Maria Grazia, Patrick Chien, John Tidy, Christianne A.R. Lok, Gitta Turowski, Yalck K. Eysbouts, Su Harma, Ginette Rosseel, Ulrike Meyer-Hamme, Erika Utracka, Jocelyne Attia, Mehmet Harma, Olesya Solheim, Matthew C Winter, Jean Pierre Lotz, Vesna Kesic, Sophie Patrier, Muge Harma, Janne Kaern, Magdalena Miedzińska, Sinan Ozalp, Eva-Maria Grischke, Amit Mayer, Leigh Bowman, Emelie Wallin, Hind Hamad Elmalik, Leon F.A.G. Massuger
Publikováno v:
European Journal of Cancer, 130, pp. 228-240
European journal of cancer (Oxford, England, 130, 228-240. Elsevier Limited
European Journal of Cancer, 130, 228-240
European journal of cancer (Oxford, England, 130, 228-240. Elsevier Limited
European Journal of Cancer, 130, 228-240
Background and aim Gestational trophoblastic disease (GTD) is a heterogeneous group of disorders characterised by abnormal proliferation of trophoblastic tissue. Since GTD and its malignant sequel gestational trophoblastic neoplasia (GTN) are rare di
Autor:
Matthew C Winter, Daniel Rea, Peter Stephens, Rebecca Roylance, Nicholas C. Turner, Jeremy P Braybrooke, Hannah Bye, Lucy Kilburn, Claire Snowdon, Sarah Kernaghan, Iain R. Macpherson, Judith M Bliss, Richard D. Baird, Mike Hubank, Abeer M Shaaban, Andrew M Wardley, Katie Wilkinson, Alistair Ring, Mark Tuthill, Jacinta Abraham, Katrina Randle, Belinda Kingston, David Cameron, Olga Oikonomidou, Laura Moretti
Publikováno v:
Cancer Research. 80:GS3-06
Background: Circulating tumour DNA (ctDNA) testing may provide a more current assessment of the genetic profile of advanced breast cancer (BC) compared with analysis of the primary tumour, with repeat advanced disease biopsy conducted infrequently in
Autor:
Peter Stephens, Belinda Kingston, Andrew M Wardley, Nicholas C. Turner, Iain R. Macpherson, Rebecca Roylance, Judith M Bliss, Jeremy P Braybrooke, Richard D. Baird, Sarah Kernaghan, Mark Tuthill, Olga Oikonomidou, Jacinta Abraham, Lucy Kilburn, Katie Wilkinson, Matthew C Winter, Alistair Ring
Publikováno v:
Cancer Research. 80:P1-19
Background: Activation of the AKT pathway can result from diverse rare genetic events, including mutation of AKT1, AKT2/3 E17K, and through inactivating mutation or homozygous deletion of PTEN. AKT1 mutations and genetic loss of PTEN are associated w